Atossa Therapeutics (ATOS)
2.41
-0.02 (0.82%)
Upcoming Events
Latest Headlines
Atos achieves CMMC 2.0 Level 2 certification, strengthening readiness for mission-critical and complex defense programs
July 23, 2026 12:59 PM - Globe NewsWire
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
July 21, 2026 8:30 AM - PR NewsWire
Rodman & Renshaw Starts Atossa Genetics (ATOS) at Buy
July 7, 2026 7:50 AM - StreetInsider
Atossa Therapeutics closes $4.5 million registered direct offering
June 12, 2026 5:31 PM - StreetInsider
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
June 12, 2026 5:31 PM - PR NewsWire
Form 424B5 ATOSSA THERAPEUTICS,
June 12, 2026 9:17 AM - SEC Filing
Atossa Therapeutics raises $4.5 million in registered direct offering
June 11, 2026 8:01 AM - StreetInsider
Form 8-K ATOSSA THERAPEUTICS, For: Jun 10
June 11, 2026 8:00 AM - SEC Filing
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
June 11, 2026 8:00 AM - PR NewsWire
Atossa presents preclinical data on breast cancer drug at ASCO 2026
May 27, 2026 8:30 AM - StreetInsider
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
May 27, 2026 8:30 AM - PR NewsWire
Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
May 20, 2026 4:45 PM - PR NewsWire
Atos Selected by Viasat to Modernize Global Digital Workplace Operations
May 19, 2026 11:09 AM - Globe NewsWire
Form 4 ATOSSA THERAPEUTICS, For: May 12 Filed by: Steinhart Richard I
May 14, 2026 6:32 PM - SEC Filing
Form 4 ATOSSA THERAPEUTICS, For: May 12 Filed by: Chen Shu-Chih
May 14, 2026 4:28 PM - SEC Filing
Form 4 ATOSSA THERAPEUTICS, For: May 12 Filed by: Remmel H. Lawrence
May 14, 2026 4:26 PM - SEC Filing
Form 4 ATOSSA THERAPEUTICS, For: May 12 Filed by: Finn Jonathan
May 14, 2026 4:26 PM - SEC Filing
Form 4 ATOSSA THERAPEUTICS, For: May 12 Filed by: Galli Stephen J
May 14, 2026 4:25 PM - SEC Filing
Form 4 ATOSSA THERAPEUTICS, For: May 12 Filed by: Cigler Tessa
May 14, 2026 4:25 PM - SEC Filing
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
May 14, 2026 8:30 AM - PR NewsWire
Form 8-K ATOSSA THERAPEUTICS, For: May 08
May 8, 2026 8:45 AM - SEC Filing
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
May 8, 2026 8:45 AM - PR NewsWire
Form 10-Q ATOSSA THERAPEUTICS, For: Mar 31
May 8, 2026 8:31 AM - SEC Filing
Form 8-K ATOSSA THERAPEUTICS, For: May 07
May 8, 2026 8:00 AM - SEC Filing
Atossa publishes trial data showing endoxifen reduces breast density
May 6, 2026 8:31 AM - StreetInsider
Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
May 6, 2026 8:30 AM - PR NewsWire
Atos extends CNA partnership with $500 million infrastructure deal
May 5, 2026 10:49 AM - StreetInsider
Atos secures $500 million multi-year infrastructure deal with CNA
May 5, 2026 10:49 AM - StreetInsider
Atos and CNA strengthen long-term strategic partnership through new multi-year infrastructure services agreement
May 5, 2026 10:49 AM - Globe NewsWire
Atossa gets FDA rare pediatric disease status for McCune-Albright drug
May 4, 2026 8:30 AM - StreetInsider
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
May 4, 2026 8:30 AM - PR NewsWire
Full Article List
